(Q34386193)

1 August 2017

1 reference

title

Cancer immunotherapy: insights from transgenic animal models (English)

1 reference

1 August 2017

1 reference

McLaughlin PM

1

1 reference

1 August 2017

Kroesen BJ

series ordinal

2

1 reference

1 August 2017

Harmsen MC

series ordinal

3

1 reference

1 August 2017

de Leij LF

series ordinal

4

1 reference

1 August 2017

publication date

1 October 2001

1 reference

Critical Reviews in Oncology Hematology

1 August 2017

published in

1 reference

1 August 2017

volume

40

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

53-76

1 reference

Cancer control in susceptible groups: opportunities and challenges

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Cancer gene and immunotherapy: recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Advances in cancer vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

How tumors escape immune destruction and what we can do about it.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The role of FasL-induced apoptosis in immune privilege

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The coming of age of tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Advances in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Recombinant antibody constructs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Insights into cancer from transgenic mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Transgenesis in rats: technical aspects and models

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Molecular cloning and expression of carcinoembryonic antigen gene family members.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Generation of human monoclonal antibodies against colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Establishment and characterisation of human carcinoembryonic antigen transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Carcinoembryonic antigen-transgenic mice: a model for tumor immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Treatment of prostate cancer: watchful waiting, radical prostatectomy, and cryoablation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Progress in active specific immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Human prostate-specific antigen: structural and functional similarity with serine proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The distribution of PSA, cathepsin‐D, and pS2 in BPH and cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Prostate cancer in a transgenic mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Epithelial mucin genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The biology of the 17-1A antigen (Ep-CAM)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The occurrence of mouse-type oligosaccharides in mouse-human chimeric immunoglobulin G

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

A rat lung cancer model based on intrapulmonary implantation of tumour material

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

T cell tolerance to Mlsa encoded antigens in T cell receptor V beta 8.1 chain transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Selection of highly transfectable variant from mouse mastocytoma P815.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

HLA polymorphisms and evolution

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The HLA crossroad in tumor immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The use of human leucocyte antigen class I transgenic mice to investigate human immune function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Genetic epidemiology of Greenland

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Expression and function of HLA-A2.1 in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Targeting p53 as a general tumor antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Tumor necrosis factor: a pleiotropic cytokine and therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Cytokine therapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-alpha and transforming growth factor-beta mRNA production

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Gamma-ray irradiation induces B7.1 costimulatory molecule neoexpression in various murine tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Genetic immunization against neu/erbB2 transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The fate of adoptively transferred antigen-specific T cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Clonal deletion of thymocytes as a tumor escape mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Targeting tumor cells with bispecific antibodies and T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Skin allograft rejection in CD28-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The emerging role of CTLA-4 as an immune attenuator

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

The threshold for autoimmune T cell killing is influenced by B7-1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet beta cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Human IgG Fc receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900129-3

7 January 2021

10.1016/S1040-8428(00)00129-3

Identifiers

DOI

1 reference

1 August 2017

1 reference